Many in the healthcare industry are currently focused on building large databases of patient profiles based on genomic data that may someday be used to customize and individualize therapy for diseases ranging from cancer to infectious diseases and beyond.
One of the challenges that arise from accumulating all of this data is whether or not therapy based on genomic profiles can account for the substantial and continuous variability in treatment response between patients. More importantly, each patient’s body changes due to constantly altered drug regimens or surgical procedures during the course of therapy. Drug synergy and incompatibility can vary within the same person at any time of their care, drastically affecting their treatment outcomes. Strategies are needed to tackle this issue if we are to develop truly personalized and precise medicine.
Optimizing the drug-dose ratios during combination therapy for a population or a specific patient has, until now, been virtually impossible. The search space for identifying these doses and ratios is basically infinite. It’s the equivalent of looking for a needle in a galaxy. To address this and other roadblocks to realizing personalized and optimized medicine, KYAN Therapeutics has pioneered a groundbreaking digital medicine technology platform using Phenotypic Personalized Medicine (PPM)TM. PPM uniquely matches patient responses to combination therapy to drive two powerful capabilities:
1) Unbiased identification of novel combination therapies and specific drug-dose ratios that are optimized for both safety and efficacy
2) Individualized patient drug regimens by adjusting the dosing of any number of drugs to ensure the best possible treatment response during the duration of their care.
KYAN achieves both of these objectives without the need for any complex disease or genomic information.
Our digital technology platform can identify and separate the factors that drive the optimal outcomes observed with its therapies, identify new druggable targets, and optimize new drug therapy combinations. This creates a continuous optimization therapy cycle for the patient.
In overcoming the roadblocks to personalized medicine, KYAN reduces the costs, accelerates the timeline, and eliminates the risk of drug development – opening the door to a new era of personalized medicine for all.
KYAN’s tech has been tested and validated across the in vitro, in vivo, and clinical stages. It is applicable towards every patient, every disease indication and every drug, from small molecules, to biologics and immunotherapies. By developing personalized, customized drug therapies, the days of clinicians, drug firms, and worst of all, patients not knowing if an experimental drug will work may finally be over.
Dean Ho is Professor in the Division of Oral Biology and Medicine at the UCLA School of Dentistry, and Bioengineering at the UCLA Henry Samueli School of Engineering and Applied Science. He is also Co-Founder of KYAN Therapeutics.